The Ferrous Awakens
There are times when leading a resistance is essential for the survival of an ideal or a civilization. But not all resistance results in an outcome that is good for the whole. This is particularly true of drug resistance. Antibiotic resistance, for example, can lead to the uncontrolled proliferation of deadly pathogens, and resistance to chemotherapeutics and targeted therapeutics are major causes of deadly cancer relapse.
To understand how some cancer cell subpopulations are able to resist drug treatment, scientists have mainly tried to identify resistant clones-cells that have gained their drugresisting superpowers through genetic mutations. However, more recently researchers have begun to expand the scope of their search, focusing their attention now on rebel cancer cells that use non-mutational escape tactics.
Scientists have observed that many rebel cells use a common trick to evade annihilation; they enter into what is known as a mesenchymal state typically characteristic of bone, cartilage, muscle, and fat cells, which can be identified by a unique pattern of cellular gene expression. To develop countermeasures against this type of insurrection, Stuart Schreiber and colleagues took a chemical biology approach to probe the vulnerabilities of cells when they are in a mesenchymal state. Their study, reported earlier this year , demonstrated how they were able to use a high-throughput small molecule screen to find chemical compounds that selectively kill cancer cell lines that are more mesenchymal in nature.
They key element which made their study possible was the calculation of mesenchymal-like scores for each of 516 carcinoma cell lines, using gene expression data from drug-resistant cancers in a mesenchymal state. The authors correlated these scores with the cytotoxic effects of various small molecule compounds and found that mesenchymal state cells can be killed selectively by chemical activators of an iron-dependent form of cell death, called ferroptosis (Stockwell et al., 2017) .
Ferroptosis is caused by cytotoxic lipid radicals, formed when ferrous iron reacts with lipid peroxides. The chemical ferroptosis activators that selectively kill mesenchymal state cells work by inhibiting an important defensive protein called GPX4 (Yang et al., 2014) . GPX4 enzymatically reduces lipid peroxides within cell membranes to lipid alcohols so that iron can no longer react, bringing balance to the ferrous. Scientists had previously hypothesized that ferroptosis activation could be one therapeutic way of countering resistant cancer cells, but the extent to which this strategy could work was unknown (Dixon et al., 2012) .
A new study led by Frank McCormick and Michael McManus (Hangauer et al., 2017) now demonstrates that resistant cells from several different cancers and drug treatments critically depend on GPX4 to survive. To arrive at this conclusion, the authors first conduct a new small molecule screen. This time, instead of looking for compounds that kill cancer cells that have a particular pattern of gene expression, they look for compounds that selectively kill truly resistant breast cancer cells-those which have evaded therapeutic drug treatment (regardless of their gene expression profiles). They too discover that ferroptosis activators are some of the best resister-fighting agents. Importantly, the authors show that genetically identical parental cells-not yet exposed to therapeutic drug-are unaffected by the same ferroptosis activators (these were not the cells they were looking for). By demonstrating the reversibility of the vulnerability, they confirm that the rebel cells were employing cell-state evasion tactics as opposed to mutational ones.
Expanding their work, the authors show that a GPX4 vulnerability accompanies resistance in a range of cancers by demonstrating that ferroptosis activators effectively destroy breast, melanoma, lung, and ovarian cancer resister cells, each having survived different therapeutic treatments. Again, there is little effect on untreated parental cells, indicating that this vulnerability is unique to resisters and can be safely used on most cells.
To cap off their study, Hangauer et al. want to prove that in animals the GPX4 defense system is a targetable weakness of resistant cancer cells. But there's a catch: the only ferroptosis activators currently available do not have the ability to circulate throughout the body. The authors must therefore devise an alternative way to take out the cancer cell's GPX4 defense system in vivo.
Their solution is to use a xenograft relapse model where they knock out GPX4 in cancer seeding cells before injecting them into mice, but then mask the effect of the knockout by co-administering the lipophilic antioxidant ferrostatin-1. In this scenario, the GPX4 defense is unnecessary while the antioxidant is present (preventing cytotoxic lipid radical formation through a GPX4-independent method). But when ferrostatin-1 is removed, the GPX4-deficiency is unmasked, awakening ferroptosis. Using this neat chemical genetic trick, they convincingly show that GPX4 is required for tumor relapse.
A new hope is that this work will lead to full cures through the development of new clinical strategies to destroy drugresistant cancer cells by taking aim at the GPX4 defense system and inducing ferroptotic cell death. For this hope to materialize, scientists must address several important questions: What is the relative importance of the ferroptotic pathway in human cancers compared to other mechanisms of resistance, including mutational mechanisms? How should we go about identifying relapsed tumors with ferroptosis vulnerabilities in patients? When and for how long would we need to use ferroptosis activators to prevent relapse? How safe would this approach be in humans? Time will tell, but for now, the ferrous is strong.
